Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CPRX NASDAQ:SVA NASDAQ:VKTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPRXCatalyst Pharmaceuticals$30.86+6.6%$25.04$19.05▼$32.56$3.54B0.721.96 million shs2.82 million shsSVASinovac Biotech$6.47$6.47$5.73▼$8.75$644.66M0.79N/AN/AVKTXViking Therapeutics$31.31-1.4%$33.64$22.96▼$43.15$3.69B0.722.34 million shs1.96 million shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPRXCatalyst Pharmaceuticals0.00%-1.81%+16.40%+13.96%+15.70%SVASinovac Biotech0.00%0.00%0.00%0.00%0.00%VKTXViking Therapeutics0.00%-9.06%-13.79%+2.01%+2.18%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPRXCatalyst Pharmaceuticals$30.86+6.6%$25.04$19.05▼$32.56$3.54B0.721.96 million shs2.82 million shsSVASinovac Biotech$6.47$6.47$5.73▼$8.75$644.66M0.79N/AN/AVKTXViking Therapeutics$31.31-1.4%$33.64$22.96▼$43.15$3.69B0.722.34 million shs1.96 million shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPRXCatalyst Pharmaceuticals0.00%-1.81%+16.40%+13.96%+15.70%SVASinovac Biotech0.00%0.00%0.00%0.00%0.00%VKTXViking Therapeutics0.00%-9.06%-13.79%+2.01%+2.18%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPRXCatalyst Pharmaceuticals 3.50Strong Buy$34.0010.17% UpsideSVASinovac Biotech 0.00N/AN/AN/AVKTXViking Therapeutics 2.85Moderate Buy$95.50205.01% UpsideCurrent Analyst Ratings BreakdownLatest CPRX, VKTX, and SVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/1/2026VKTXViking Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$125.004/30/2026VKTXViking Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$95.004/30/2026VKTXViking Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$105.00 ➝ $100.004/27/2026VKTXViking Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/20/2026VKTXViking Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026CPRXCatalyst Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy (B-)3/27/2026CPRXCatalyst Pharmaceuticals Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/26/2026VKTXViking Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoveragePeer Perform3/25/2026CPRXCatalyst Pharmaceuticals Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/23/2026VKTXViking Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$102.003/3/2026CPRXCatalyst Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPRXCatalyst Pharmaceuticals$588.99M6.41$3.12 per share9.90$7.76 per share3.98SVASinovac Biotech$361.37M1.78$2.03 per share3.19N/A∞VKTXViking TherapeuticsN/AN/AN/AN/A$4.32 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPRXCatalyst Pharmaceuticals$214.33M$1.6918.2610.020.9436.39%36.47%31.85%5/11/2026 (Estimated)SVASinovac Biotech$90.90MN/AN/AN/AN/AN/AN/AN/AN/AVKTXViking Therapeutics-$359.64M-$4.14N/AN/AN/AN/A-71.31%-65.35%N/ALatest CPRX, VKTX, and SVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026CPRXCatalyst Pharmaceuticals$0.64N/AN/AN/A$148.18 millionN/A4/29/2026Q1 2026VKTXViking Therapeutics-$1.01-$1.37-$0.36-$1.37N/AN/A2/11/2026Q4 2025VKTXViking Therapeutics-$0.89-$1.38-$0.49-$1.38N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCPRXCatalyst PharmaceuticalsN/AN/AN/AN/AN/ASVASinovac BiotechN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPRXCatalyst PharmaceuticalsN/A6.085.82SVASinovac BiotechN/AN/AN/AVKTXViking TherapeuticsN/A5.725.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPRXCatalyst Pharmaceuticals79.22%SVASinovac BiotechN/AVKTXViking Therapeutics76.03%Insider OwnershipCompanyInsider OwnershipCPRXCatalyst Pharmaceuticals10.40%SVASinovac Biotech12.79%VKTXViking Therapeutics5.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPRXCatalyst Pharmaceuticals80122.35 million109.42 millionOptionableSVASinovac Biotech3,26199.64 million86.89 millionOptionableVKTXViking Therapeutics20116.11 million109.95 millionOptionableCPRX, VKTX, and SVA HeadlinesRecent News About These CompaniesViking Therapeutics: Market Betting On Big Upside Through 2030May 5 at 12:00 PM | seekingalpha.comViking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026May 5 at 8:41 AM | finance.yahoo.comViking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026May 5 at 7:05 AM | prnewswire.comHere's Exactly Why Wall Street Thinks Viking Therapeutics Stock Could Soar 207% Over the Next 12 MonthsMay 4 at 7:32 PM | fool.comViking Therapeutics (NASDAQ:VKTX) Trading 7.4% Higher - Still a Buy?May 4 at 6:40 PM | marketbeat.comViking Therapeutics' (VKTX) "Buy" Rating Reaffirmed at BTIG ResearchMay 4 at 8:22 AM | marketbeat.comHC Wainwright Brokers Decrease Earnings Estimates for VKTXMay 4 at 1:02 AM | americanbankingnews.comHC Wainwright Has Pessimistic Outlook of VKTX Q2 EarningsMay 4 at 1:00 AM | marketbeat.comWhy Viking Therapeutics (VKTX) Is Down 8.4% After Expanding VK2735 Phase 3 Obesity Program And LossMay 2 at 11:25 PM | finance.yahoo.comAnalysts Are Bullish on These Healthcare Stocks: Viking Therapeutics (VKTX), Regeneron (REGN)May 1, 2026 | theglobeandmail.comPiper Sandler Sticks to Their Buy Rating for Viking Therapeutics (VKTX)May 1, 2026 | theglobeandmail.comViking Therapeutics faces timeline risk, but upside could be hugeMay 1, 2026 | msn.comViking Therapeutics Faces Timeline Risk—But Upside Could Be Huge...May 1, 2026 | marketbeat.comViking Therapeutics, Inc. $VKTX Shares Sold by Pictet Asset Management Holding SAMay 1, 2026 | marketbeat.comVKTX stock slips premarket: A surprise weight loss drug beats Novo Nordisk in early animal testsApril 30, 2026 | msn.comVKTX Q1 Earnings Miss on Higher Phase 3 Development CostsApril 30, 2026 | finance.yahoo.comVKTX Q1 Earnings Miss on Higher Phase 3 Development CostsApril 30, 2026 | zacks.comViking Therapeutics Earnings: Q3 Maintenance Study Data A Potential WildcardApril 30, 2026 | seekingalpha.comViking Therapeutics Inc (VKTX) Q1 2026 Earnings Call Highlights: Strategic Advancements Amid ...April 30, 2026 | finance.yahoo.comViking Therapeutics, Inc. (VKTX) Q1 2026 Earnings Call TranscriptApril 30, 2026 | seekingalpha.comVKTX shares drop after hours on larger Q1 losses but retail eyes the launch of its obesity pipelineApril 30, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026The War Won't Last Forever: 3 Stocks That Could Lead the RecoveryBy Bridget Bennett | April 8, 20263 Discounted Stocks With Strong Rebound PotentialBy Chris Markoch | April 6, 2026Viking Therapeutics Faces Timeline Risk—But Upside Could Be HugeBy Chris Markoch | May 1, 2026CPRX, VKTX, and SVA Company DescriptionsCatalyst Pharmaceuticals NASDAQ:CPRX$30.86 +1.92 (+6.63%) Closing price 04:00 PM EasternExtended Trading$31.20 +0.34 (+1.10%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.Sinovac Biotech NASDAQ:SVA$6.47 0.00 (0.00%) As of 05/4/2026Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.Viking Therapeutics NASDAQ:VKTX$31.31 -0.45 (-1.42%) Closing price 04:00 PM EasternExtended Trading$31.06 -0.25 (-0.80%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
